WO2008009866A3 - Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3 - Google Patents

Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3 Download PDF

Info

Publication number
WO2008009866A3
WO2008009866A3 PCT/FR2007/051702 FR2007051702W WO2008009866A3 WO 2008009866 A3 WO2008009866 A3 WO 2008009866A3 FR 2007051702 W FR2007051702 W FR 2007051702W WO 2008009866 A3 WO2008009866 A3 WO 2008009866A3
Authority
WO
WIPO (PCT)
Prior art keywords
modafinil
antagonist
receptor
combination
inverse agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2007/051702
Other languages
English (en)
Other versions
WO2008009866A2 (fr
Inventor
Jean-Charles Schwartz
Jeanne-Marie Lecomte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioprojet SC
Original Assignee
Bioprojet SC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioprojet SC filed Critical Bioprojet SC
Priority to CA002659754A priority Critical patent/CA2659754A1/fr
Priority to MX2009000809A priority patent/MX2009000809A/es
Priority to BRPI0714843-7A priority patent/BRPI0714843A2/pt
Priority to EA200970141A priority patent/EA017090B1/ru
Priority to EP07823620A priority patent/EP2043624A2/fr
Priority to US12/374,517 priority patent/US20090312367A1/en
Priority to CN2007800327045A priority patent/CN101528213B/zh
Priority to JP2009521313A priority patent/JP2009544673A/ja
Publication of WO2008009866A2 publication Critical patent/WO2008009866A2/fr
Publication of WO2008009866A3 publication Critical patent/WO2008009866A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'association de modafinil et d'au moins un antagoniste ou agoniste inverse du récepteur H3 de l'histamine, utile notamment pour le traitement de la narcolepsie-cataplexie et plus généralement des troubles du sommeil, de la vigilance ou de l'attention.
PCT/FR2007/051702 2006-07-21 2007-07-20 Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3 Ceased WO2008009866A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA002659754A CA2659754A1 (fr) 2006-07-21 2007-07-20 Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
MX2009000809A MX2009000809A (es) 2006-07-21 2007-07-20 Asociacion de modafinil y de un antagonista o agonista inverso del receptor h3.
BRPI0714843-7A BRPI0714843A2 (pt) 2006-07-21 2007-07-20 composiÇço farmacÊutica, utilizaÇço de modafinil para a preparaÇço de um medicamento, e, kit
EA200970141A EA017090B1 (ru) 2006-07-21 2007-07-20 Комбинация модафинила и 1-{3-[3-(4-хлорфенил)пропокси]пропил}пиперидина
EP07823620A EP2043624A2 (fr) 2006-07-21 2007-07-20 Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
US12/374,517 US20090312367A1 (en) 2006-07-21 2007-07-20 Combination of modafinil and an antagonist or inverse agonist of the h3 receptor
CN2007800327045A CN101528213B (zh) 2006-07-21 2007-07-20 莫达非尼和h3受体拮抗体或反向激动剂的组合
JP2009521313A JP2009544673A (ja) 2006-07-21 2007-07-20 モダフィニルとｈ３レセプターのアンタゴニストまたはインバースアゴニストとの組み合わせ

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0606697 2006-07-21
FR0606697A FR2903904A1 (fr) 2006-07-21 2006-07-21 Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3

Publications (2)

Publication Number Publication Date
WO2008009866A2 WO2008009866A2 (fr) 2008-01-24
WO2008009866A3 true WO2008009866A3 (fr) 2008-03-20

Family

ID=37708188

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/051702 Ceased WO2008009866A2 (fr) 2006-07-21 2007-07-20 Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3

Country Status (10)

Country Link
US (1) US20090312367A1 (fr)
EP (1) EP2043624A2 (fr)
JP (1) JP2009544673A (fr)
CN (1) CN101528213B (fr)
BR (1) BRPI0714843A2 (fr)
CA (1) CA2659754A1 (fr)
EA (1) EA017090B1 (fr)
FR (1) FR2903904A1 (fr)
MX (1) MX2009000809A (fr)
WO (1) WO2008009866A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104114538B (zh) * 2012-01-16 2016-04-13 葛兰素史克知识产权发展有限公司 治疗用途
WO2014164969A1 (fr) * 2013-03-13 2014-10-09 Aerial Biopharma, Llc Traitement de la cataplexie

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069313A1 (en) * 1999-08-16 2003-04-10 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
US20050222151A1 (en) * 2004-03-31 2005-10-06 Carruthers Nicholas I Non-Imidazole heterocyclic compounds
WO2006103546A2 (fr) * 2005-04-01 2006-10-05 Bioprojet Traitement de la maladie de parkinson, de l'apnee obstructive du sommeil, de la demence avec corps de lewy, de la demence vasculaire, avec des ligands du recepteur h3 d'histamine a alkylamines non imidazoles
WO2006138604A1 (fr) * 2005-06-17 2006-12-28 Janssen Pharmaceutica N.V. Composés d'hexahydro-pyrrolo-isoquinoline pour le traitement des troubles du snc

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04006777A (es) * 2002-01-11 2004-11-10 Abbott Lab Ligandos de receptor de histamina-3 para condiciones diabeticas.
FR2856596B1 (fr) * 2003-06-27 2007-04-27 Bioprojet Soc Civ Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes.
JP2008543880A (ja) * 2005-06-17 2008-12-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ナフチリジン化合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069313A1 (en) * 1999-08-16 2003-04-10 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
US20050222151A1 (en) * 2004-03-31 2005-10-06 Carruthers Nicholas I Non-Imidazole heterocyclic compounds
WO2006103546A2 (fr) * 2005-04-01 2006-10-05 Bioprojet Traitement de la maladie de parkinson, de l'apnee obstructive du sommeil, de la demence avec corps de lewy, de la demence vasculaire, avec des ligands du recepteur h3 d'histamine a alkylamines non imidazoles
WO2006138604A1 (fr) * 2005-06-17 2006-12-28 Janssen Pharmaceutica N.V. Composés d'hexahydro-pyrrolo-isoquinoline pour le traitement des troubles du snc

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BOYD B ET AL: "Armodafinil. Treatment of excessive sleepiness [alpha]1- adrenoceptor agonist", DRUGS OF THE FUTURE 2006 SPAIN, vol. 31, no. 1, January 2006 (2006-01-01), pages 17 - 21, XP002419716, ISSN: 0377-8282 *
BROOKS STEPHEN ET AL: "Novel therapies for narcolepsy.", EXPERT OPINION ON INVESTIGATIONAL DRUGS DEC 2002, vol. 11, no. 12, December 2002 (2002-12-01), pages 1821 - 1827, XP002419717, ISSN: 1354-3784 *
ESBENSHADE T A ET AL: "Histamine H3 receptor antagonists: Preclinical promise for treating obesity and cognitive disorders", MOLECULAR INTERVENTIONS 2006 UNITED STATES, vol. 6, no. 2, April 2006 (2006-04-01), pages 77 - 88, XP009078910, ISSN: 1534-0384 *
MIGNOT E ET AL: "Emerging therapies in narcolepsy-cataplexy", SLEEP 01 JUN 2005 UNITED STATES, vol. 28, no. 6, 1 June 2005 (2005-06-01), pages 754 - 763, XP009078900, ISSN: 0161-8105 *
STARK H: "Recent advances in histamine H3/H4 receptor ligands", EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 13, no. 6, 2003, pages 851 - 865, XP002298271, ISSN: 1354-3776 *

Also Published As

Publication number Publication date
EP2043624A2 (fr) 2009-04-08
MX2009000809A (es) 2009-02-03
JP2009544673A (ja) 2009-12-17
BRPI0714843A2 (pt) 2013-05-21
FR2903904A1 (fr) 2008-01-25
WO2008009866A2 (fr) 2008-01-24
EA017090B1 (ru) 2012-09-28
CN101528213B (zh) 2012-02-15
US20090312367A1 (en) 2009-12-17
CA2659754A1 (fr) 2008-01-24
EA200970141A1 (ru) 2009-08-28
CN101528213A (zh) 2009-09-09

Similar Documents

Publication Publication Date Title
WO2008076754A3 (fr) Composés et compositions utilisés comme inhibiteurs de l'activité du récepteur cannabinoïde 1
WO2010120695A3 (fr) Composés agonistes du récepteur 5-ht4 pour le traitement des troubles cognitifs
WO2007126957A3 (fr) Nouveaux composés
WO2008048991A3 (fr) Composés organiques
MX2010010407A (es) Derivados de 4-aminociclohexanos sustituidos.
WO2010123930A3 (fr) Thérapies à base de ligand de récepteur chimiosensible
WO2005097825A3 (fr) Variants de bmp-7 ayant des proprietes ameliorees
UA95464C2 (en) Pyridopyrazine derivatives and use thereof
IL232619A0 (en) Preparations suitable for the treatment of diseases of the spine and related disorders and conditions
WO2009002423A3 (fr) Dérivés de guanine polycycliques et leurs procédés d'utilisation
NO20085051L (no) Behandling av gastrointestinale forstyrrelser med CGRP-antagonister
CL2007003637A1 (es) Procedimiento para la preparacion de derivados benzimida piperacinilo y diazepanilo utiles para el tratamiento de trastornos y afecciones intermediadas por un receptor histamina.
PT2229369T (pt) Derivados de 6,7-dialcoxi-quinazolina úteis para tratamento de distúrbios relacionados com o cancro
EP2209759A4 (fr) Fabrication de 1,1,1,2,3,3-hexafluoropropane and 1,1,1,2-tétrafluoropropane par l'hydrogénation catalytique
EA201190140A1 (ru) Производные циклопропиламида, направленно действующие на гистаминовый н3-рецептор
CL2011000061A1 (es) Compuestos derivados de tetrahidrocinolinas, inhibidores de la 11-beta-hsd1; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la diabetes, obesidad, trastornos de ingestion de comida o dislipidemia.
WO2010086828A3 (fr) Anticorps monoclonaux agonistes anti-trkb
WO2008100629A3 (fr) Mimétiques de la glutathione peroxydase pour le traitement de dermatoses
WO2010077976A3 (fr) Antagoniste du récepteur de la prokinéticine et ses utilisations
EP2005194A4 (fr) Procédés utilisant de l'hémoglobine pour la prophylaxie, le diagnostic et/ou le traitement de troubles de la rétine
TW200744584A (en) Use of mGluR5 antagonists (ESP. AFQ056) in GI (ESP. GERD)
BRPI0722057A2 (pt) Composto, prodroga, composição farmacêutica, método para prevenir ou tratar distúrbio do sono, e, uso do composto.
WO2008009866A3 (fr) Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
WO2011097336A3 (fr) Agonistes hautement sélectifs du récepteur 5-ht(2c) ayant une activité antagoniste au niveau du récepteur 5-ht(2b)
WO2007047397A3 (fr) Nouveaux composes heterocycliques

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780032704.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07823620

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/000809

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 12374517

Country of ref document: US

Ref document number: 2009521313

Country of ref document: JP

Ref document number: 2007823620

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2659754

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 380/MUMNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200970141

Country of ref document: EA

NENP Non-entry into the national phase

Ref country code: RU

ENP Entry into the national phase

Ref document number: PI0714843

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090121